Actionable news
All posts from Actionable news
Actionable news in ACAD: ACADIA Pharmaceuticals Inc.,

2Q Snapshot: H.C. Wainwright Weighs In on ACADIA Pharmaceuticals Inc. (ACAD)

In ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) second-quarter report, investors got a first glimpse of Nuplazid’s early launch in Parkinson’s disease psychosis (PDP). ACAD reported EPS of $0.63, compared to consensus estimates of $0.49 and a net loss of $71.3MM. Nuplazid sales in 2Q16 were $0.1MM compared to consensus of $0.8MM.

H.C. Wainwright analyst Andrew Fein commented, “We guide investors’ attention away from revenue this quarter, that while de minimis, was in line with our expectations and, we believe, that of the Street more broadly. Instead, we draw attention to factors that have the potential to impact 3Q and 4Q, independent of NUPLAZID’s potential to be successful in the long-term, including...